Rituximab after ASCT prolongs survival for young MCL patients

Share :
Published: 5 Dec 2016
Views: 1946
Rating:
Save
Prof Steven Le Gouill - Nantes Medical University, Nantes, France

Prof Le Gouill speaks with ecancertv at ASH 2016 about the outcomes of the LYMA trial in France and Belgium, in which rituximab was assessed as part of maintenance therapy for young mantle cell lymphoma patients.

He describes the addition of rituximab as worthy of being a new standard of care in this setting, with extensions to patient EFS, PFS and overall survival.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.